Pemafibrate Tablets 0.1mg (Parmodia® / パルモディア錠0.1mg)

JPY ¥3,600

Japanese Antihyperlipidemic Agent (Pemafibrate 0.1mg). Oral selective PPARα modulator for hyperlipidemia including familial forms, administered twice daily. 100 tablets (10 tablets x 10). Mfd. by Kowa Co., Ltd., Japan.

Bulk deal
Quantity Discount Discounted price
5 - 9 8% JPY ¥3,312
10 - 19 12% JPY ¥3,168
20 + 18% JPY ¥2,952
SKU: PAR-01-TAB Category:

Description

Product Overview / 商品概要

Parmodia Tablets 0.1mg (パルモディア錠0.1mg)
Generic: Pemafibrate / ペマフィブラート
Therapeutic Category: Antihyperlipidemic Agent / 高脂血症治療剤
Manufactured by: Kowa Co., Ltd. / 興和株式会社

Composition & Specification / 組成・規格

Active Ingredient: Pemafibrate 0.10mg per tablet / 1錠中 ペマフィブラート 0.10mg
Additives: Lactose hydrate, Croscarmellose sodium, Microcrystalline cellulose, Hydroxypropylcellulose, Magnesium stearate, Hypromellose, Triethyl citrate, Light anhydrous silicic acid, Titanium oxide, Carnauba wax / 乳糖水和物、クロスカルメロースNa、結晶セルロース、ヒドロキシプロピルセルロース、ステアリン酸Mg、ヒプロメロース、クエン酸トリエチル、軽質無水ケイ酸、酸化チタン、カルナウバロウ
Appearance: White, round, scored film-coated tablet. Diameter: 7.1mm, Thickness: 2.9mm, Weight: 125mg. Identification marking: Parmodia 0.1
外観: 白色、円形の割線入りフィルムコーティング錠である。直径7.1mm、厚さ2.9mm、重量125mg、識別表示:パルモディア 0.1

Indications / 効能効果

EN: Hyperlipidemia (including familial hyperlipidemia)
JA: 高脂血症(家族性を含む)

Dosage and Administration / 用法用量

EN: The usual adult dose is 0.1mg of pemafibrate administered orally twice daily, in the morning and evening. The dose may be adjusted according to age and symptoms, but the maximum dose is 0.2mg twice daily.
JA: 通常、成人にはペマフィブラートとして1回0.1mgを1日2回朝夕に経口投与する。なお、年齢、症状に応じて適宜増減するが、最大用量は1回0.2mgを1日2回までとする。

Contraindications / 禁忌

EN: Patients with a history of hypersensitivity to any component of this product; patients with severe hepatic impairment, Child-Pugh class B or C liver cirrhosis, or biliary obstruction; patients with gallstones; pregnant women or women who may be pregnant; patients receiving cyclosporine or rifampicin
JA: 本剤の成分に対し過敏症の既往歴のある患者、重篤な肝障害・Child-Pugh分類B又はCの肝硬変のある患者あるいは胆道閉塞のある患者、胆石のある患者、妊婦又は妊娠している可能性のある女性、シクロスポリン・リファンピシンを投与中の患者

Regulatory Information / 規制情報

Approval No.: 22900AMX00581
Sales Started: June 2018 / 2018年6月
Classification Code: 872183
Storage: Store at room temperature / 室温保存
Shelf Life: 3 years / 3年

Packaging / 包装

Main Package (for sale): 100 tablets (10 tablets x 10) / 100錠(10錠×10)
Other Available Packages (by special order): PTP: 100 tablets (10 tablets x 10), 500 tablets (10 tablets x 50), 1000 tablets (10 tablets x 100); Bulk: 500 tablets (plastic bottle)

Full product insert (添付文書) is attached as a downloadable PDF. For detailed precautions, drug interactions, and safety information, please refer to the official package insert.

Additional information

重さ 0.15 kg

Reviews

There are no reviews yet.

Be the first to review “Pemafibrate Tablets 0.1mg (Parmodia® / パルモディア錠0.1mg)”

メールアドレスが公開されることはありません。 が付いている欄は必須項目です

Export from Japan — Pemafibrate Tablets 0.1mg (Parmodia®

🏭 Supply & Origin

  • Country of Origin: Japan
  • Regulatory Standard: PMDA (Japan) / GMP Compliant
  • Pharmacopoeia: Japanese Pharmacopoeia (JP)
  • Supplier: Mate Co., Ltd. — Licensed Pharmaceutical Wholesaler (License No. B14309, Osaka)
  • Supply Capacity: Full-line sourcing through Japan's regulated distribution channels

🚚 Shipping & Trade Terms

  • Incoterms: FOB Kansai International Airport (KIX)
  • Shipping: Air freight via B/L or AWB
  • Payment: 100% T/T in advance
  • Lead Time: 2-4 weeks after payment confirmation
  • Available Regions: EU, LATAM, APAC, Middle East, Africa

Request a Quotation

For pricing, MOQ, and regulatory documentation, contact our export team:

Email: kurimoto@mate-osaka.co.jp
Tel: +81-72-665-5736

All exports are conducted through proper regulatory procedures including customs clearance, B/L or AWB documentation, and T/T advance payment. We do not engage in hand-carry, cash transactions, or sales to unlicensed parties.